The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival
Abstract
Adedayo A. Onitilo, MD, MSCR, FACP, Jessica M. Engel, MSN, FNP-BC, Robert T. Greenlee, PhD and Bickol N. Mukesh, PhD Adedayo A. Onitilo, MD, MSCR, FACP, Department of Hematology/Oncology, Marshfield Clinic Weston Center, 3501 Cranberry Blvd, Weston, Wisconsin 54401 Jessica M. Engel, MSN, FNP-BC, Department of Hematology/Oncology, Marshfield Clinic, 1000 North Oak Avenue, Marshfield, Wisconsin 54449 Robert T. Greenlee, PhD, Epidemiology Research Center, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, Wisconsin 54449 Bickol N. Mukesh, PhD, Biomedical Informatics Research Center, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, Wisconsin 54449. Current affiliation: Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, TX 76134 Reprint Requests: Adedayo A. Onitilo, MD, MSCR, FACP, Marshfield Clinic Weston Center, 3501 Cranberry Boulevard, Weston, WI 54476, Tel: 715-393-1400, Fax: 715-393-1399, Email: onitilo.adedayo{at}marshfieldclinic.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Cited by
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,508
Epidemiological characteristics of and risk factors for breast cancer in the world
Momenimovahed, Z., & Salehiniya, H. (2019) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s176070 · Cited by 1,050
Stack, E. C., Wang, C., Roman, K. A., & Hoyt, C. C. (2014) · Methods · doi:10.1016/j.ymeth.2014.08.016 · Cited by 768
Stromal cells in tumor microenvironment and breast cancer
Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., & Wang, J. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9415-3 · Cited by 671
“five subtypes (luminal A, luminal B, HER2-positive, basallike, and normal-like) according to different gene expressions [23], among different subtypes or in the same subtype, patients have different prognosis and different lengths of survival [24, 25], which may contribute to heterogeneous stroma, as suggested by our…”
Medrek, C., Pontén, F., Jirström, K., & Leandersson, K. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-306 · Cited by 647
Braman, N. M., Etesami, M., Prasanna, P., Dubchuk, C., Gilmore, H., Tiwari, P., Plecha, D., & Madabhushi, A. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0846-1 · Cited by 632
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0627 · Cited by 598
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 555
Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
O'Brien, K. M., Cole, S. R., Tse, C.-K., Perou, C. M., Carey, L. A., Foulkes, W. D., Dressler, L. G., Geradts, J., & Millikan, R. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1533 · Cited by 429
Exosomal miRNAs as cancer biomarkers and therapeutic targets
Thind, A., & Wilson, C. (2016) · Journal of Extracellular Vesicles · doi:10.3402/jev.v5.31292 · Cited by 404
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Hu, R., Dawood, S., Holmes, M. D., Collins, L. C., Schnitt, S. J., Cole, K., Marotti, J. D., Hankinson, S. E., Colditz, G. A., & Tamimi, R. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2021 · Cited by 396
Distinct functions of AKT isoforms in breast cancer: a comprehensive review
Hinz, N., & Jücker, M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0450-3 · Cited by 355
Tamura, K., Tsurutani, J., Takahashi, S., Iwata, H., Krop, I. E., Redfern, C., Sagara, Y., Doi, T., Park, H., Murthy, R. K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30097-x · Cited by 352
Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring
McGuire, A., Brown, J. A. L., & Kerin, M. J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9551-7 · Cited by 329
Triple negative breast cancer: unmet medical needs
Pal, S. K., Childs, B. H., & Pegram, M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1293-1 · Cited by 322
Mechanisms of immune evasion in breast cancer
Bates, J. P., Derakhshandeh, R., Jones, L., & Webb, T. J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4441-3 · Cited by 291
Park, S., Koo, J. S., Kim, M. S., Park, H. S., Lee, J. S., Lee, J. S., Kim, S. I., & Park, B.-W. (2012) · The Breast · doi:10.1016/j.breast.2011.07.008 · Cited by 284
Breast cancer models: Engineering the tumor microenvironment
Bahcecioglu, G., Basara, G., Ellis, B. W., Ren, X., & Zorlutuna, P. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.02.006 · Cited by 213
Determining breast cancer biomarker status and associated morphological features using deep learning
Gamble, P., Jaroensri, R., Wang, H., Tan, F., Moran, M., Brown, T., Flament-Auvigne, I., Rakha, E. A., Toss, M., Dabbs, D. J., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00013-3 · Cited by 154
Regulation of estrogen signaling and breast cancer proliferation by an ubiquitin ligase TRIM56
Xue, M., Zhang, K., Mu, K., Xu, J., Yang, H., Liu, Y., Wang, B., Wang, Z., Li, Z., Kong, Q., et al. (2019) · Oncogenesis · doi:10.1038/s41389-019-0139-x · Cited by 97
Robertson, C. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.11.009 · Cited by 45
Woo, H. D., Park, K.-S., Ro, J., & Kim, J. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.635261 · Cited by 41
“The present study showed consistency with previous studies demonstrating that triple negative breast cancer had the worst recurrence-free survival over other types of breast cancer (14,20).”
BackgroundResultThe ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression
Zhu, J., Li, X., Su, P., Xue, M., Zang, Y., & Ding, Y. (2020) · Oncogene · doi:10.1038/s41388-020-01464-z · Cited by 39
Metadata
- Authors
- Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N.
- Venue
- Clinical Medicine & Research
- Publisher
- Marshfield Clinic Research Institute
- Published
- 2009-02-26
- Volume
- 7
- Issue
- 1-2
- Pages
- 4-13
- ISSN
- 1539-4182 (ISSN-L)
- 1554-6179
- OpenAlex
- W4241664300
- Cited by
- 765
- References
- 29
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.